Revealing Interim Results from Candel Therapeutics
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company dedicated to advancing biological immunotherapies to combat cancer, has announced noteworthy interim data stemming from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) targeting recurrent glioblastoma. This announcement coincides with a significant publication in the peer-reviewed journal Science Translational Medicine.
Publication Highlights from the Clinical Trial
In a recent publication titled “Serial Multiomics Uncovers Anti-Glioblastoma Responses Not Evident by Routine Clinical Analyses,” researchers meticulously analyzed 97 serial tumor biopsies collected from two patients undergoing repeated treatments with CAN-3110. This study was led by Dr. E. Antonio Chiocca, Executive Director of the Center for Tumors of the Nervous System at the Mass General Brigham Cancer Institute, as part of a collaborative effort known as the Break Through Cancer framework.
Understanding the Impact of CAN-3110
The study revealed critical insights into the tumor behavior after treatment. The integration of various datasets showcased a discrepancy between the immune response and traditional imaging results, indicating that CAN-3110 managed to alter the tumor's microenvironment. Remarkably, the study recorded a complete pathological response in one patient, suggesting that the presence of immune cells might mistakenly indicate tumor growth on MRI scans if not analyzed correctly.
Important Discoveries in the Trial
Among significant findings were the emergence of new effector memory T cell clonotypes directly targeting CAN-3110 epitopes. This highlights the dual mechanism behind CAN-3110’s efficacy, emphasizing both the viral and tumor-specific immune responses that occur following the immunotherapy treatment.
Latest Survival Data and Patient Outcomes
Candel Therapeutics also presented updated survival statistics for all participants in the phase 1b clinical trial. The median overall survival (mOS) reported was 11.8 months for arm A and 12.0 months for arm B after a single dose of CAN-3110. Encouragingly, two patients are still alive after extended monitoring, showing promising signs of long-term survival following treatment.
Dosing Insights and Future Directions
Among those in arm C, nine patients underwent multiple CAN-3110 administrations. The trial has revealed that more than four injections may not necessarily yield better outcomes. These findings will play a vital role in shaping the design of future pivotal trials.
Potential of CAN-3110 in Treating Recurrent Glioblastoma
Dr. Francesca Barone, Chief Scientific Officer at Candel, reflected on the challenges posed by glioblastoma. She noted that the advancements seen with CAN-3110 exemplify how the treatment could potentially enhance survival rates far beyond historical averages in this aggressive cancer type.
Looking Forward with CAN-3110
CEO Dr. Paul Peter Tak expressed optimism regarding the potential of their viral immunotherapy platform to make substantial strides in combating glioblastoma. A phase 2 clinical trial of CAN-3110 is in the planning stages, aiming to further validate these promising results.
Exploring CAN-3110: A Unique Immunotherapy Option
CAN-3110 is recognized as an innovative oncolytic viral immunotherapy harnessing the capabilities of the herpes simplex virus-1 (HSV-1). The ongoing evaluations aim to confirm its efficacy and safety as a treatment against recurrent high-grade glioma (rHGG). Candel is dedicated to making significant breakthroughs in this demanding therapy area.
About Candel Therapeutics
Candel Therapeutics is on the frontier of immunotherapy, focused on designing multimodal treatments that can adapt to individual patient needs. The company has developed two platforms harnessing genetically modified adenovirus and HSV, aiming to generate robust anti-tumor responses. It boasts successful trial outcomes in non-small cell lung cancer and prostate cancer, establishing a strong track record in innovative cancer treatments.
Frequently Asked Questions
What positive results have been announced for CAN-3110?
Candel Therapeutics announced interim data showing CAN-3110 can induce significant changes in the tumor microenvironment, improving treatment outcomes for glioblastoma patients.
Who led the recent study on CAN-3110?
The study was led by Dr. E. Antonio Chiocca, who is the Executive Director of the Center for Tumors of the Nervous System at Mass General Brigham Cancer Institute.
What was the median overall survival reported for patients?
The updated median overall survival reported was 11.8 months for arm A and 12.0 months for arm B after a single injection of CAN-3110.
How does CAN-3110 work?
CAN-3110 is designed as an oncolytic viral immunotherapy that activates immune responses while also targeting cancer cells directly within the tumor.
What are Candel Therapeutics' plans for future trials?
Candel plans to develop further phase 2 trials to validate the positive results observed with CAN-3110 in treating recurrent glioblastoma.
